As of April 28, 2026, Sagimet Biosciences's top three insider holders are Enterprise Associates 13 Lp New (TenPercentOwner, 3.85Mn shares), Enterprise Associates 13 Lp New (TenPercentOwner, 3.85Mn shares), Enterprise Associates 13 Lp New (TenPercentOwner, 3.85Mn shares).
| Holder | Position | Shares (Direct) | Shares (Indirect) | Report Date |
|---|---|---|---|---|
| Enterprise Associates 13 Lp New | - | 3,850,275 | 0 | 20 Jul, 2023 |
| Enterprise Associates 13 Lp New | - | 3,850,275 | 0 | 20 Jul, 2023 |
| Enterprise Associates 13 Lp New | - | 3,850,275 | 0 | 20 Jul, 2023 |
| Patrick J Kerins | - | 13,139 | 3,000,275 | 31 Jan, 2024 |
| Forest Baskett | - | 0 | 3,011,575 | 31 Jan, 2024 |
| Scott D Sandell | - | 0 | 3,007,272 | 31 Jan, 2024 |
| Enterprise Associates 13 Lp New | - | 3,000,275 | 0 | 31 Jan, 2024 |
| Partners 13, Limited Partnership Nea | - | 0 | 3,000,275 | 31 Jan, 2024 |
| Partners 13, Limited Partnership Nea | - | 0 | 3,000,275 | 31 Jan, 2024 |
| Partners 13, Limited Partnership Nea | - | 0 | 3,000,275 | 31 Jan, 2024 |
| Beth C Seidenberg | - | 84,768 | 1,946,350 | 20 Jul, 2023 |
| Jinzi Jason Wu | - | 0 | 1,654,701 | 20 Jul, 2023 |
| David Happel | President Ceo | 805,621 | 0 | 20 Feb, 2026 |
| Elizabeth Rozek | Chief Legal Admin. Officer | 234,959 | 0 | 20 Feb, 2026 |
| Eduardo Bruno Martins | Chief Medical Officer | 147,296 | 0 | 20 Feb, 2026 |
| George Kemble | Executive Chairman | 81,005 | 0 | 21 Nov, 2025 |
| Thierry Chauche | Chief Financial Officer | 59,688 | 0 | 20 Feb, 2026 |
| Merdad Parsey | - | 12,794 | 0 | 20 Jul, 2023 |
* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.
| Transaction Date | Insider Name | Security Class | Transaction Type | Shares Traded | Price | Shares Remaining | Ownership | Code |
|---|---|---|---|---|---|---|---|---|
| 19 Feb, 2026 | Thierry Chauche | Series A Common Stock | A | 44,000 | $0.00 | 59,688 | D | A |
| 19 Feb, 2026 | Elizabeth Rozek | Series A Common Stock | A | 44,000 | $0.00 | 234,959 | D | A |
| 19 Feb, 2026 | David Happel | Series A Common Stock | A | 128,000 | $0.00 | 805,621 | D | A |
| 19 Feb, 2026 | Eduardo Bruno Martins | Series A Common Stock | A | 44,000 | $0.00 | 147,296 | D | A |
| 19 Feb, 2026 | Thierry Chauche | Stock Option (Right to Buy) | A | 88,000 | $0.00 | 88,000 | D | A |
| 19 Feb, 2026 | Eduardo Bruno Martins | Stock Option (Right to Buy) | A | 88,000 | $0.00 | 88,000 | D | A |
| 19 Feb, 2026 | Elizabeth Rozek | Stock Option (Right to Buy) | A | 88,000 | $0.00 | 88,000 | D | A |
| 19 Feb, 2026 | David Happel | Stock Option (Right to Buy) | A | 256,000 | $0.00 | 256,000 | D | A |
| 10 Feb, 2026 | Thierry Chauche | Series A Common Stock | D | 1,312 | $5.36 | 15,688 | D | S |
| 10 Feb, 2026 | David Happel | Series A Common Stock | D | 12,101 | $5.36 | 677,621 | D | S |
| 10 Feb, 2026 | Eduardo Bruno Martins | Series A Common Stock | D | 3,640 | $5.36 | 103,296 | D | S |
| 10 Feb, 2026 | Elizabeth Rozek | Series A Common Stock | D | 2,622 | $5.36 | 190,959 | D | S |
| 20 Nov, 2025 | George Kemble | Series A Common Stock | D | 37,688 | $7.69 | 81,005 | D | S |
| 04 Nov, 2025 | Elizabeth Rozek | Series A Common Stock | A | 9,855 | $0.00 | 193,581 | D | A |
| 04 Nov, 2025 | Elizabeth Rozek | Stock Option (Right to Buy) | A | 13,367 | $0.00 | 13,367 | D | A |
| 21 Jul, 2025 | David Happel | Series A Common Stock | D | 65,478 | $9.13 | 689,722 | D | S |
| 21 Jul, 2025 | Elizabeth Rozek | Series A Common Stock | D | 10,780 | $9.13 | 183,726 | D | S |
| 21 Jul, 2025 | Eduardo Bruno Martins | Series A Common Stock | D | 8,277 | $9.13 | 106,936 | D | S |
| 09 Jun, 2025 | George Kemble | Stock Option (Right to Buy) | A | 32,250 | $0.00 | 32,250 | D | A |
| 09 Jun, 2025 | Anne M. Phillips | Stock Option (Right to Buy) | A | 27,268 | $0.00 | 27,268 | D | A |